Clinical Trials /

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

NCT04673448

Description:

This phase IB trial evaluates the effect of niraparib and TSR-042 in treating patients with BRCA-mutated breast, pancreas, ovary, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as TSR-042, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and TSR-042 may kill more cancer cells.

Related Conditions:
  • Breast Carcinoma
  • Fallopian Tube Carcinoma
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Primary Peritoneal Carcinoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
  • Official Title: Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer

Clinical Trial IDs

  • ORG STUDY ID: RG1005140
  • SECONDARY ID: NCI-2020-11636
  • NCT ID: NCT04673448

Conditions

  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • BRCA-Mutated Malignant Neoplasm
  • BRCA-Mutated Metastatic Breast Carcinoma
  • BRCA-Mutated Ovarian Carcinoma
  • Metastatic Breast Carcinoma
  • Metastatic Fallopian Tube Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Ovarian Carcinoma
  • Metastatic Pancreatic Carcinoma
  • Metastatic Primary Peritoneal Carcinoma
  • Prognostic Stage III Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Prognostic Stage IV Breast Cancer AJCC v8
  • Stage III Fallopian Tube Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Stage III Pancreatic Cancer AJCC v8
  • Stage III Primary Peritoneal Cancer AJCC v8
  • Stage IIIA Fallopian Tube Cancer AJCC v8
  • Stage IIIA Ovarian Cancer AJCC v8
  • Stage IIIA Primary Peritoneal Cancer AJCC v8
  • Stage IIIA1 Fallopian Tube Cancer AJCC v8
  • Stage IIIA1 Ovarian Cancer AJCC v8
  • Stage IIIA2 Fallopian Tube Cancer AJCC v8
  • Stage IIIA2 Ovarian Cancer AJCC v8
  • Stage IIIB Fallopian Tube Cancer AJCC v8
  • Stage IIIB Ovarian Cancer AJCC v8
  • Stage IIIB Primary Peritoneal Cancer AJCC v8
  • Stage IIIC Fallopian Tube Cancer AJCC v8
  • Stage IIIC Ovarian Cancer AJCC v8
  • Stage IIIC Primary Peritoneal Cancer AJCC v8
  • Stage IV Fallopian Tube Cancer AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Stage IV Primary Peritoneal Cancer AJCC v8
  • Stage IVA Fallopian Tube Cancer AJCC v8
  • Stage IVA Ovarian Cancer AJCC v8
  • Stage IVA Primary Peritoneal Cancer AJCC v8
  • Stage IVB Fallopian Tube Cancer AJCC v8
  • Stage IVB Ovarian Cancer AJCC v8
  • Stage IVB Primary Peritoneal Cancer AJCC v8
  • Unresectable Breast Carcinoma
  • Unresectable Fallopian Tube Carcinoma
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Ovarian Carcinoma
  • Unresectable Pancreatic Carcinoma
  • Unresectable Primary Peritoneal Carcinoma

Interventions

DrugSynonymsArms
DostarlimabANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042Treatment (niraparib, dostarlimab)
NiraparibMK-4827, MK4827Treatment (niraparib, dostarlimab)

Purpose

This phase IB trial evaluates the effect of niraparib and TSR-042 in treating patients with BRCA-mutated breast, pancreas, ovary, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as TSR-042, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and TSR-042 may kill more cancer cells.

Detailed Description

      OUTLINE:

      Patients receive niraparib orally (PO) once daily (QD) on days 1-28 of cycle 1. Beginning
      cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on
      day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or
      unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and
      dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 30 days, every 6 months for
      2 years, and then annually for up to 5 years.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (niraparib, dostarlimab)ExperimentalPatients receive niraparib PO QD on days 1-28 of cycle 1. Beginning cycle 2, patients receive niraparib PO QD on days 1-21 and dostarlimab intravenously (IV) on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 6, patients receive niraparib PO QD on days 1-42 and dostarlimab IV on day 1. Cycles repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
  • Dostarlimab
  • Niraparib

Eligibility Criteria

        Inclusion Criteria:

          -  Participant must have breast, pancreas, ovary, fallopian tube or primary peritoneal
             cancer that is unresectable or metastatic, with a pathogenic mutation in BRCA1 or
             BRCA2 (either germline or somatic) as confirmed by next generation gene sequencing
             such as University of Washington (UW) OncoPlex assay or equivalent, and who have
             experienced progression or been intolerant to standard therapies for their disease.

               -  Breast cancer patients with or without HER2+, estrogen receptor (ER)+, and/or
                  progesterone receptor (PR)+ disease, as determined by pathological report, are
                  allowed

          -  Participant must be able and willing to undergo pre-treatment and on-treatment biopsy

          -  Participant must have life expectancy of 4 months or greater

          -  Tumor must be measurable according to Response Evaluation Criteria in Solid Tumors
             (RECIST)1.1 criteria

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of =< 1

          -  Participant must be >= 18 years of age

          -  Patient must be able to tolerate oral medication

          -  Absolute neutrophil count >= 1,500/uL

          -  Platelets >= 100,000/uL

          -  Hemoglobin >= 9 g/dL

          -  Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine
             clearance >= 60 mL/min using the Cockcroft-Gault equation

          -  Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR
             direct bilirubin =< 1 x ULN

          -  Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver
             metastases are present, in which case they must be =< 5 x ULN

          -  International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless
             patient is receiving anticoagulant therapy as long as PT or partial thromboplastin
             (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial
             thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant
             therapy as long as PT or PTT is within therapeutic range of intended use of
             anticoagulants

          -  Asymptomatic patients with stable brain metastases must have no evidence of bleeding
             and no need for steroids or anti-epileptic medications for at least 7 days prior to
             day 1

          -  Participants receiving corticosteroids may continue as long as their dose is stable
             for at least 4 weeks prior to initiating protocol therapy

          -  Female participant has a negative urine or serum pregnancy test within 7 days prior to
             taking study treatment if of childbearing potential and agrees to abstain from
             activities that could result in pregnancy from screening through 180 days after the
             last dose of study treatment or is of nonchildbearing potential. Nonchildbearing
             potential is defined as follows (by other than medical reasons):

               -  >= 45 years of age and has not had menses for > 1 year

               -  Patients who have been amenorrhoeic for < 2 years without history of a
                  hysterectomy and oophorectomy must have a follicle stimulating hormone value in
                  the postmenopausal range upon screening evaluation

               -  Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.
                  Documented hysterectomy or oophorectomy must be confirmed with medical records of
                  the actual procedure or confirmed by an ultrasound. Tubal ligation must be
                  confirmed with medical records of the actual procedure, otherwise the patient
                  must be willing to use 2 adequate barrier methods throughout the study, starting
                  with the screening visit through 180 days after the last dose of study treatment.
                  Information must be captured appropriately within the site's source documents.
                  Note: Abstinence is acceptable if this is the established and preferred
                  contraception for the patient

          -  Participant must agree to not breastfeed during the study or for 180 days after the
             last dose of study treatment

          -  Male participant agrees to use an adequate method of contraception starting with the
             first dose of study treatment through 180 days after the last dose of study treatment.
             Note: Abstinence is acceptable if this is the established and preferred contraception
             for the patient

          -  Participant must be able to understand the study procedures and agree to participate
             in the study by providing written informed consent

          -  Participant must agree to not donate blood during the study or for 90 days after the
             last dose of study treatment

          -  Prior treatment with a PARP inhibitor is allowed as long as patient has not had
             previous exposure to immune checkpoint inhibitor including inhibitors of PD1, PD-L1 or
             CTLA4

          -  Prior treatment with immune checkpoint inhibitor including inhibitors of PD1, PD-L1 or
             CTLA4 is allowed as long as patient has not had previous exposure to PARP inhibitor

        Exclusion Criteria:

          -  Participant must not be simultaneously enrolled in any interventional clinical trial

          -  Participant must not have had major surgery =< 3 weeks prior to initiating protocol
             therapy and participant must have recovered from any surgical effects

          -  Prior treatment with both PARP inhibitor and immune checkpoint inhibitor blockade
             either sequentially or together including inhibitors of PD1, PD-L1 or CTLA4 is not
             allowed. Patients may have had either PARP inhibitor or Immune checkpoint inhibitor
             previously but not within 3 months of starting treatment

          -  Participant must not have received investigational therapy =< 4 weeks, or within a
             time interval less than at least 5 half-lives of the investigational agent, whichever
             is shorter, prior initiating protocol therapy

          -  Participant must not have had radiation therapy encompassing > 20% of the bone marrow
             within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol
             therapy

          -  Participant must not have a known hypersensitivity to niraparib and dostarlimab
             (TSR-042) components or excipients

          -  Participant must not have received a transfusion (platelets or red blood cells) =< 4
             weeks prior to initiating protocol therapy

          -  Participant must not have received colony stimulating factors (e.g., granulocyte
             colony-stimulating factor, granulocyte macrophage colony stimulating factor, or
             recombinant erythropoietin) within 4 weeks prior initiating protocol therapy

          -  Participant has had any known grade 3 or 4 anemia, neutropenia or thrombocytopenia due
             to prior chemotherapy that persisted > 4 weeks and was related to the most recent
             treatment

          -  Participant must not have any known history of myelodysplastic syndrome (MDS) or acute
             myeloid leukemia (AML)

          -  Participant must not have a serious, uncontrolled medical disorder, nonmalignant
             systemic disease, or active, uncontrolled infection. Examples include, but are not
             limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial
             infarction, uncontrolled major seizure disorder, unstable spinal cord compression,
             superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining
             informed consent

          -  Participant must not have had diagnosis, detection, or treatment of another type of
             cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell
             carcinoma of the skin and in situ cervical cancer that has been definitively treated
             or a BRCA-related cancer (i.e., breast, prostate, pancreas or ovarian)

          -  Participant must not have a known partial or complete bowel obstruction that is
             incompatible with oral feeding and/or absorption of oral medications

          -  Patient experienced >= grade 3 immune-related adverse event (AE) with prior
             immunotherapy, with the exception of non-clinically significant lab abnormalities

          -  Participant has a diagnosis of immunodeficiency or has received systemic steroid
             therapy or any other form of immunosuppressive therapy within 7 days prior to
             initiating protocol therapy

          -  Participant has a known history of human immunodeficiency virus (type 1 or 2
             antibodies)

          -  Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg]
             reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative]
             is detected)

          -  Participant has an active autoimmune disease that has required systemic treatment in
             the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or
             immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
             etc.) is not considered a form of systemic treatment

          -  Participant must not have a history of interstitial lung disease

          -  Participant has received a live vaccine within 14 days of initiating protocol therapy
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Best objective response
Time Frame:5 years
Safety Issue:
Description:Will be defined as a complete response (CR) or partial response (PR), confirmed and unconfirmed, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 using investigator's review.

Secondary Outcome Measures

Measure:Incidence of adverse events
Time Frame:5 years
Safety Issue:
Description:Will assess events leading to dose reduction, events leading to permanent treatment discontinuation, overall incidence and Common Terminology Criteria for Adverse Events criteria grade of adverse events, as well as relatedness of adverse events to treatment, incidence of great 2 or greater non-hematologic toxicity and grade 3 or 4 hematologic toxicity, causes of death.
Measure:Progression-free survival (PFS)
Time Frame:Time from the start of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression, assessed up to 5 years
Safety Issue:
Description:Progression will be assessed by method (RECIST v.1.1 etc.) criteria using (independent central or investigator's) review. PFS for patients last known to be alive and progression-free will be censored at the date of last follow-up.
Measure:Duration of response (DOR)
Time Frame:Time from the initial response (CR or PR) until the time of first documentation of disease progression, assessed up to 5 years
Safety Issue:
Description:Will be assessed by RECIST version 1.1 using investigator's review. DOR for patients last known to be alive and progression-free will be censored at the date of last follow-up.
Measure:Disease control (DC)
Time Frame:5 years
Safety Issue:
Description:Will be defined as a best response of CR, PR or stable disease (SD) (of at least 6 months) as assessed by RECIST version 1.1 using investigator's review. DC for patients not known to have a best response of CR or PR, or SD for at least 6 months from the start of study treatment will be coded as lacking disease control.
Measure:Overall survival
Time Frame:From the start of study treatment to the date of death by any cause, assessed up to 5 years
Safety Issue:
Description:

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:University of Washington

Last Updated

December 17, 2020